NASDAQ: BIOABioage Labs Inc Stock
$4.52+0.03 (+0.67%)
Updated Jun 13, 2025
BIOA Price
$4.52
Fair Value Price
N/A
Market Cap
$162.04M
52 Week Low
$2.88
52 Week High
$26.62
P/E
N/A
P/B
0.52x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.1
Operating Cash Flow
N/A
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BIOA Overview
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BIOA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
BIOA
Ranked#49 of 59
Ranked#49 of 59
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.93 | A | |
| $5.24 | A | |
| $6.88 | A |
Be the first to know about important BIOA news, forecast changes, insider trades & much more!
BIOA News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BIOA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIOA is good value based on its book value relative to its share price (0.52x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.26x)
P/B vs Industry Valuation
BIOA's short-term assets ($324.81M) exceed its short-term liabilities ($23.74M)
Short-term Liabilities Financials
BIOA's short-term assets ($324.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more BIOA due diligence checks available for Premium users.
Valuation
BIOA fair value
Fair Value of BIOA stock based on Discounted Cash Flow (DCF)
Price
$4.52
Fair Value
-$4.23
Undervalued by
206.75%
BIOA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-23.1x
Market
31.36x
BIOA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.52x
Industry
2.26x
BIOA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIOA's financial health
Profit margin
Revenue
$1.5M
Net Income
-$12.9M
Profit Margin
-891%
Assets to liabilities
Assets
$343.8M
Liabilities
$30.7M
Debt to equity
0.1
BIOA's short-term assets ($324.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOA's short-term assets ($324.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.4M
Investing
-$78.0M
Financing
-$1.5M
BIOA vs Pharmaceutical Stocks
Bioage Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.